Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,070,437

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 5:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EBS vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Here's Why You Should Retain Pacific Biosciences Stock Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

OSMT or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OSMT vs. ILMN: Which Stock Is the Better Value Option?

ALXN vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

ALXN vs. ILMN: Which Stock Is the Better Value Option?

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

by Zacks Equity Research

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

EBS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EBS vs. ILMN: Which Stock Is the Better Value Option?

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

by Zacks Equity Research

Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.

Illumina (ILMN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 37.86% and 4.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?

by Zacks Equity Research

Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.

QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

by Zacks Equity Research

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

by Zacks Equity Research

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

Illumina, Broad Institute Partner on Secondary Genomic Analysis

by Zacks Equity Research

The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed at $300.15 in the latest trading session, marking a +1.65% move from the prior day.

Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

by Zacks Equity Research

Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

by Zacks Equity Research

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

Mark Vickery headshot

Top Research Reports for Target, Illumina & T-Mobile US

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS).

Illumina (ILMN) Stock Moves 0.72%: What You Should Know

by Zacks Equity Research

In the latest trading session, Illumina (ILMN) closed at $305.20, marking a +0.72% move from the previous day.